- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00001024
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
A Multicenter, Open-Label Study of Viral Burden in Peripheral Blood Versus Lymphoid Tissue Before and After Antiretroviral Therapy in HIV-Infected Individuals Without AIDS (NOTE: One Arm Receives no Treatment)
Immunopathogenesis objectives: To compare and quantitatively determine HIV burden and HIV replication in peripheral blood (PB) and lymphoid tissue (LT). To determine the degree to which antiretroviral therapy alters HIV replication in LT.
Clinical objectives: To gain insight into the degree of correlation between immunologic surrogate markers for HIV disease (e.g., CD4, beta-2 microglobulin) as compared to measures of HIV replication in PB and LT. To assess changes in PB and LT viral burden after antiretroviral therapy and to determine its ability to predict an antiviral response.
One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.
Sixteen antiretroviral-naive patients are randomized to either remain antiretroviral-naive (no treatment) or receive zidovudine daily (treatment). Additionally, 16 patients with 26 or more weeks of ongoing zidovudine (AZT) therapy are randomized to either continue on their prestudy AZT regimen or add didanosine (ddI) daily to their baseline AZT dose. Patients remain on their assigned treatment arms for 8 weeks. A lymph node biopsy is performed on day 0 and at week 8. Patients are evaluated at weeks 2, 4, 6, 8 and 9.
Studietype
Registrering
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Palo Alto, California, Forente stater, 94304
- Palo Alto Veterans Affairs Health Care System
-
San Francisco, California, Forente stater, 94115
- Kaiser Permanente Med Ctr
-
San Francisco, California, Forente stater, 94115
- Mount Zion Med Ctr / UCSF
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Univ of Illinois
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Univ of Maryland at Baltimore
-
-
New York
-
Stony Brook, New York, Forente stater, 117948153
- SUNY / Health Sciences Ctr at Stony Brook
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke Univ Med Ctr
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15261
- Univ of Pittsburgh
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
Concurrent Medication:
Allowed:
- Chemoprophylaxis against M. tuberculosis, therapy for oral candidiasis, and short courses (up to 10 days) of acyclovir for herpes lesions.
- Antibiotics as clinically indicated.
- Pneumococcal vaccine and hepatitis B vaccine as medically indicated.
- Regularly prescribed medications such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives, or other medications deemed appropriate by the patient's primary care provider.
Recommended:
- PCP prophylaxis if patient's CD4 count falls below 200 cells/mm3 during the study.
Concurrent Treatment:
Allowed:
- Alternative therapies such as vitamins and acupuncture.
Patients must have:
- Documented HIV infection.
- At least two palpable lymph nodes above the waist.
- CD4 counts >= 350 cells/mm3 (if previously antiretroviral-naive) or >= 250 cells/mm3 (if receiving ongoing AZT therapy).
Patients with prior AZT therapy must have received a stable dose of 300-600 mg daily for 26 or more weeks.
Prior Medication:
Required in patients with prior ongoing therapy:
- AZT at dose of 300-600 mg daily for at least 26 weeks.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Severe malabsorption.
- Current AIDS-related opportunistic infection, AIDS dementia, AIDS-wasting syndrome, or an AIDS-related malignancy other than minimal Kaposi's sarcoma disease.
- Current medical problems that may interfere with the evaluation of AZT or increase the potential toxicity of AZT (e.g., significant liver disease, diabetes, significant cardiovascular disease, seizure disorders, lymphoma, acute or chronic pancreatitis, or febrile illness).
- Current diagnosis of malignancy for which systemic therapy would be required during study.
Concurrent Medication:
Excluded:
- Ganciclovir, foscarnet, chronic acyclovir, or probenecid.
- Other proven or alleged antiretroviral or anti-HIV drugs.
- Biologic response modifiers.
- Valproic acid.
- Systemic cytotoxic chemotherapy.
- Steroids.
Concurrent Treatment:
Excluded:
- Radiation therapy.
Patients with the following prior conditions are excluded:
- Prior AIDS-related opportunistic infection, AIDS dementia, AIDS-wasting syndrome, or an AIDS-related malignancy other than minimal Kaposi's sarcoma disease.
- History of medical problems that may interfere with the evaluation of AZT or increase the potential toxicity of AZT (e.g., significant liver disease, diabetes, significant cardiovascular disease, seizure disorders, lymphoma, acute or chronic pancreatitis, or febrile illness).
- History of peripheral neuropathy (patients with prior AZT treatment only).
Prior Medication:
Excluded:
- Prior ddI therapy.
- Less than 26 weeks of prior AZT (in patients with ongoing AZT therapy only).
- Ganciclovir, foscarnet, chronic acyclovir, or probenecid.
- Cytotoxic chemotherapy within 1 month prior to study entry.
- Acute therapy for an infection or other medical illness within 14 days prior to study entry.
History of alcohol abuse (patients with prior AZT treatment).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: M Niu
- Studiestol: J Cohn
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Cohen OJ, Pantaleo G, Graziosi C, Niu M, Fauci AS. Effect of antiretroviral therapy on HIV burden and replication in lymphoid tissue. DATRI 003 Study Group. Int Conf AIDS. 1994 Aug 7-12;10(1):7 (abstract no 001B)
Studierekorddatoer
Studer hoveddatoer
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- Sykdommer i immunsystemet
- HIV-infeksjoner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Revers transkriptasehemmere
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Anti-HIV-midler
- Antiretrovirale midler
- Antimetabolitter
- Zidovudin
- Didanosin
Andre studie-ID-numre
- DATRI 003
- 11734 (Registeridentifikator: DAIDS ES Registry Number)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Children's Hospital Medical Center, CincinnatiAvsluttetAllogen hematopoetisk celletransplantasjonForente stater
-
University of Colorado, DenverUniversity of IowaFullførtHealth Care Associated Infection | HåndhygieneForente stater
Kliniske studier på Zidovudin
-
Glaxo WellcomeUkjentHIV-infeksjonerForente stater
-
Glaxo WellcomeFullført
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbeidspartnereFullførtHIV-infeksjoner | SvangerskapThailand
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...FullførtHIV-infeksjonerForente stater, Puerto Rico
-
Glaxo WellcomeFullført
-
Glaxo WellcomeFullførtHIV-infeksjoner | LipodystrofiForente stater
-
ViiV HealthcareFullført
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...FullførtHIV-infeksjonerForente stater, Puerto Rico
-
Johann Wolfgang Goethe University HospitalGilead SciencesUkjent
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University...Fullført